

1 **Title:**

2 **Clinical presentation and differential splicing of *SRSF2*, *U2AF1* and *SF3B1* mutations in**  
3 **patients with Acute Myeloid Leukaemia**

4 **Running Head:**

5 **Characterization of SF mutations in AML**

6 Stefanos A. Bamopoulos<sup>1,2</sup>, Aarif M. N. Batcha<sup>3,4</sup>, Vindi Jurinovic<sup>1,3</sup>, Maja Rothenberg-  
7 Thurley<sup>1</sup>, Hanna Janke<sup>1</sup>, Bianka Ksienzyk<sup>1</sup>, Julia Philippou-Massier<sup>5</sup>, Alexander Graf<sup>5</sup>, Stefan  
8 Krebs<sup>5</sup>, Helmut Blum<sup>5</sup>, Stephanie Schneider<sup>1,6</sup>, Nikola Konstandin<sup>1</sup>, Maria Cristina  
9 Sauerland<sup>7</sup>, Dennis Görlich<sup>7</sup>, Wolfgang E. Berdel<sup>8</sup>, Bernhard J. Woermann<sup>9</sup>, Stefan K.  
10 Bohlander<sup>10</sup>, Stefan Canzar<sup>11</sup>, Ulrich Mansmann<sup>3,4,12,13</sup>, Wolfgang Hiddemann<sup>1,12,13</sup>, Jan  
11 Braess<sup>14</sup>, Karsten Spiekermann<sup>1,12,13</sup>, Klaus H. Metzeler<sup>1,12,13</sup> and Tobias Herold<sup>1,12,15</sup>

12

13 1 Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU  
14 Munich, Munich, Germany

15 2 Department of Hematology and Oncology (CBF), Charité University Medicine, Berlin, Ger-  
16 many

17 3 Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Mu-  
18 nich, Germany

19 4 DIFUTURE (Data integration for Future Medicine (DiFuture, [www.difuture.de](http://www.difuture.de)), LMU Munich,  
20 Munich, Germany

21 5 Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich,  
22 Germany

23 6 Institute of Human Genetics, University Hospital, LMU Munich, Munich, Germany

24 7 Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany

25 8 Department of Medicine, Hematology and Oncology, University of Münster, Münster, Ger-

26 many

27 9 German Society of Hematology and Oncology, Berlin, Germany

28 10 Leukaemia and Blood Cancer Research Unit, Department of Molecular Medicine and Pa-

29 thology, University of Auckland, Auckland, New Zealand

30 11 Gene Center, LMU Munich, Munich, Germany

31 12 German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany

32 13 German Cancer Research Center (DKFZ), Heidelberg, Germany

33 14 Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg,

34 Germany

35 15 Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München,

36 German Center for Environmental Health (HMGU), Munich, Germany

37 **Corresponding Authors:**

38 Stefanos A. Bamopoulos; stefanos.bamopoulos@charite.de

39 **and**

40 Tobias Herold, MD; Marchioninstr. 15; 81377 Munich; Germany; Phone: +49 89 4400-0; FAX:

41 +49 89 4400-74242; Email: tobias.herold@med.uni-muenchen.de

42

43 **Abstract**

44 Previous studies demonstrated that splicing factor mutations are recurrent events in  
45 hematopoietic malignancies with both clinical and functional implications. However, their  
46 aberrant splicing patterns in acute myeloid leukaemia remain largely unexplored. In this study  
47 we characterized mutations in *SRSF2*, *U2AF1* and *SF3B1*, the most commonly mutated  
48 splicing factors. In our clinical analysis of 2678 patients, splicing factor mutations showed  
49 inferior relapse-free and overall survival, however, these mutations did not represent  
50 independent prognostic markers. RNA-sequencing of 246 and independent validation in 177  
51 patients revealed an isoform expression profile highly characteristic for each individual  
52 mutation, with several isoforms showing a strong dysregulation. By establishing a custom  
53 differential splice junction usage pipeline we accurately detected aberrant splicing in splicing  
54 factor mutated samples. Mutated samples were characterized predominantly by decreased  
55 junction usage. A large proportion of differentially used junctions were novel. Targets of  
56 splicing dysregulation included several genes with a known role in leukaemia. In  
57 *SRSF2*(P95H) mutants we further explored the possibility of a cascading effect through the  
58 dysregulation of the splicing pathway. We conclude that splicing factor mutations do not  
59 represent independent prognostic markers. However, they do have genome-wide  
60 consequences on gene splicing leading to dysregulated isoform expression of several genes.

## 61 **Introduction**

62 The discovery of recurring somatic mutations within splicing factor genes in a large spectrum  
63 of human malignancies has brought attention to the critical role of splicing and its complex  
64 participation in carcinogenesis [1–3]. The spliceosome is a molecular machine assembled  
65 from small nuclear RNA (snRNA) and proteins and is responsible for intron removal (splicing)  
66 in pre-messenger RNA. In acute myeloid leukaemia (AML), splicing factor mutations occur  
67 most frequently in *SRSF2*, *U2AF1* and *SF3B1*. The splicing factors encoded by these genes  
68 are all involved in the recognition of the 3'-splice site during pre-mRNA processing.[4] Splicing  
69 factor (SF) mutations are especially common in haematopoietic malignancies, where they  
70 occur early on and remain stable throughout the disease evolution of myelodysplastic  
71 syndromes (MDS) [1,5–9]. SF mutations are also prevalent in acute myeloid leukaemia  
72 (AML), which is often the result of myeloid dysplasia progression, with reported frequencies of  
73 6-10%, 4-8% and 3% for *SRSF2*, *U2AF1* and *SF3B1* mutations respectively [2,4,10,11].  
74 SF mutations rarely co-occur within the same patient, implying the lack of a synergistic effect  
75 or synthetic lethality [1,2,6]. They are typically heterozygous point mutations, frequently  
76 coincide with other recurrent mutations in haematopoietic malignancies and are associated  
77 with aberrant splicing in genes recurrently mutated in AML [2,4,8]. Notably, the aberrant  
78 splicing patterns are distinct for each SF mutation, suggesting that SF mutations do not share  
79 the same mechanism of action and should be recognized as individual alterations [4,9,12–17].  
80 The clinical characteristics and outcome of patients with SF mutations are well defined in  
81 MDS [1,3,8,9]. Meanwhile, attempts at determining the role of SF mutations as independent  
82 prognostic markers in AML have often been limited to specific subgroups and it remains  
83 unclear whether the inferior survival associated with SF mutations is confounded by their  
84 association with older age or accompanying mutations [10,18]. Additionally, while evidence of

85 aberrant splicing due to SF mutations has emerged for many genes relevant in AML, it is yet  
86 uncertain whether and how these changes directly influence disease initiation or evolution.  
87 The aim of this study was a comprehensive analysis of the prognostic implications of SF  
88 mutations in two well-characterized and intensively treated adult AML patient cohorts  
89 amounting to a total of 2678 patients. In addition, the core functional consequences of SF  
90 mutations were explored using targeted amplicon sequencing in conjunction with RNA-  
91 sequencing on two large datasets.

## 92 **Patients and Methods**

### 93 **Patients**

94 Our primary cohort included a total of 1138 AML patients treated with intensive chemotherapy  
95 in two randomized multicenter phase 3 trials of the German AML Cooperative Group  
96 (AMLCG). Treatment regimens and inclusion criteria are described elsewhere [2]. A cohort of  
97 1540 AML patients participating in multicenter clinical trials of the German-Austrian AML  
98 Study Group (AMLSG), was used for validation [19]. Cohort composition and filtering criteria  
99 are outlined in the supplementary.

### 100 **Molecular Workup**

101 All participants of the AMLCG cohort received cytogenetic analysis, as well as targeted DNA-  
102 sequencing as described previously [2]. The subset of the AMLSG cohort included in this  
103 study received a corresponding molecular workup, described elsewhere [19].

### 104 **RNA-Sequencing and data processing**

105 Using the Sense mRNA Seq Library Prep Kit V2 (Lexogen; Vienna, Austria) 246 samples  
106 underwent poly(A)-selected, strand-specific, paired-end sequencing on a HiSeq 1500  
107 instrument (Illumina; San Diego, CA, USA). A subset of the Beat AML cohort (n=177) was  
108 used for validation [20]. The same bioinformatics analysis was used for both datasets and is  
109 described in the supplementary. The samples were aligned to the reference genome  
110 (Ensembl GRCh37 release 87) using the STAR [21] aligner with default parameters. Splice  
111 junctions from all samples were pooled, filtered and used to create a new genomic index.  
112 Multi-sample 2-pass alignments to the re-generated genome index followed, using the STAR  
113 recommended parameters for gene-fusion detection. Read counts of transcripts and genes  
114 were measured with salmon [22]. Read counts of splice junctions were extracted from the  
115 STAR output.

116

## 117 **Differential expression analysis and differential splice junction usage (DSJU)**

118 A minimum expression filter was applied prior to each differential analysis. Differentially  
119 expressed isoforms were identified with the limma [23] package after TMM-normalization [24]  
120 with edgeR [25] and weighting with voom [26,27]. A surrogate variable analysis step using the  
121 sva [28] package was included to reduce unwanted technical noise. DSJU was quantified  
122 similarly using the diffSplice function of the limma package. Both analyses are described in  
123 detail in the supplementary.

## 124 **Nanopore cDNA sequencing and analysis**

125 Total RNA was transcribed into cDNA using the TeloPrime Full-Length cDNA Amplification Kit  
126 (Lexogen) which is highly selective for polyadenylated full-length RNA molecules with 5'-cap  
127 structures. Two barcoded samples for multiplexed analysis were sequenced on the Oxford  
128 Nanopore Technologies MinION platform. Alternative isoform analysis was performed with  
129 FLAIR [29].

## 130 **Statistics**

131 Statistical analysis was performed using the R-3.4.1 [30] software package. Correlations  
132 between variables were performed using the Mann-Whitney U test and the Pearson's chi-  
133 squared test. In case of multiple testing, p-value adjustment was performed as described in  
134 the supplementary. Survival analysis was performed and visualized using the Kaplan-Meier  
135 method and the log-rank test was utilized to capture differences in relapse free survival (RFS)  
136 and overall survival (OS). Patients receiving an allogeneic stem cell transplant were censored  
137 at the day of the transplant, for both RFS and OS. Additionally, Cox regressions were  
138 performed for all available clinical parameters and recurrent aberrations. Cox multiple  
139 regression models were then built separately for RFS and OS, using all variables with an

140 unadjusted p-value < 0.1 in the single Cox regression models.



## 141 **Results**

### 142 **Clinical features of AML patients with SF mutations**

143 We characterized SF mutations in two independent patient cohorts (the AMLCG and AMLSG  
144 cohorts). Our primary cohort (AMLCG) consisted of 1119 AML patients (Figure S1), 236  
145 (21.1%) of which presented with SF mutations. The three most commonly affected SF genes,  
146 *SRSF2*, *U2AF1* and *SF3B1* were mutated in 12.1% (n=136), 3.4% (n=38) and 4.1% (n=46) of  
147 the patients (Figure 1A). In agreement with previous findings [19], SF mutations were in their  
148 majority mutually exclusive, heterozygous hotspot mutations (Figure 1B). The four most  
149 common point mutations were *SRSF2*(P95H) (n=69), *SRSF2*(P95L) (n=27), *U2AF1*(S34F)  
150 (n=18), and *SF3B1*(K700E) (n=18) mutations (Figure 1C-E). The clinical characteristics of  
151 patients harboring SF mutations are summarized in Tables 1 and S1 (AMLSG cohort), along  
152 with a statistical assessment between cohorts (Table S2). We observed a high overall degree  
153 of similarity regarding clinical features of SF mutated patients between the AMLCG and  
154 AMLSG cohorts, despite their large median age difference. Mutations in *SRSF2*, *U2AF1* and  
155 *SF3B1* occurred more frequently in secondary AML (44.7% compared to 18.2% in *de novo*  
156 AML) and were all associated with older age. As reported previously [1], *SRSF2* and *U2AF1*  
157 mutated patients were predominantly male (76.7% and 76.3%, respectively). Furthermore,  
158 patients harboring *SRSF2* mutations presented with a lower white blood cell count (WBC;  
159 median  $13.3 \times 10^9/L$  vs.  $22.4 \times 10^9/L$ ) while *U2AF1* mutated patients presented with a reduced  
160 blast percentage in their bone marrow when compared to SF wildtype patients (median 60%  
161 vs 80%).

### 162 **Associations of SF mutations and other recurrent alterations in AML**

163 In a second step, we investigated associations between SF mutations and recurrent  
164 cytogenetic abnormalities and gene mutations in AML (Figure 2). Notably, SF mutations were

165 not found in *inv(16)/t(16;16)* patients (n=124), with the exception of one *inv(16)/t(16;16)*  
166 patient harboring a *U2AF1(R35Q)* mutation. The same held true for *t(8;21)* patients (n=98),  
167 where only one patient had a rare deletion in *SRSF2*. Additionally, all patients in the AMLCG  
168 cohort presenting with an isolated trisomy 13 (n=9) also harbored an *SRSF2* mutation  
169 (p<0.001), as described previously [31].

170 Mutations in all SF genes correlated positively with mutations in *BCOR* and *RUNX1* and  
171 negatively with mutations in *NPM1*. Expectedly, *SRSF2(P95H)* and *SRSF2(P95L)* mutations  
172 shared a similar pattern of co-expression including significant pairwise associations with  
173 mutations in *ASXL1*, *IDH2*, *RUNX1* (both p<0.001) and *STAG2* (p<0.001 and p=0.002,  
174 respectively). However, apart from *IDH2* mutations where co-occurrence was comparable  
175 (OR: 3.4 vs 5.1), mutations in *ASXL1*, *RUNX1* and *STAG2* coincided more frequently with  
176 *SRSF2(P95H)* mutations. Despite this, *SRSF2(P95L)* mutations showed a slightly increased  
177 co-occurrence with other recurrent AML mutations (median 5 vs 4 mutations, p=0.046).

### 178 **Prognostic relevance of SF mutations for relapse-free survival and overall survival**

179 The prognostic impact of *SRSF2*, *U2AF1* and *SF3B1* mutations was initially assessed using  
180 Kaplan-Meier graphs and log-rank testing. All SF mutations presented with both inferior  
181 relapse-free survival (RFS) and overall survival (OS) compared to SF wildtype patients  
182 (Figures S3.1A-C and S3.2). The effect was most pronounced in *U2AF1* mutated patients with  
183 an one-year survival rate of only 29.1%, followed by *SF3B1* (40.6%) and *SRSF2* mutated  
184 patients (49.2%). Different point mutations inside the same SF gene did not differ significantly  
185 in their effect on OS.

186 To confirm the observed prognostic impact of SF mutations we performed single Cox  
187 regressions on all available clinical and genetic parameters. In agreement with the Kaplan-  
188 Meier estimates, patients harboring *SRSF2(P95H)*, *SRSF2(P95L)*, *U2AF1(S34F)* and

189 *SF3B1*(K700E) mutations had significantly reduced RFS and OS (Figures S3.1D and S4.1).  
190 To test whether any SF mutation was an independent prognostic marker, multiple Cox  
191 regression models (Figure 3) were built by integrating all parameters significantly associated  
192 ( $p < 0.1$ ) with RFS and OS in the single Cox regression models. Along with several known  
193 predictors, only *U2AF1*(S34F) mutations presented with prognostic relevance for both RFS  
194 (Hazard Ratio=2.81,  $p=0.012$ ) and OS (HR=1.90,  $p=0.034$ ) in the AMLCG cohort, but not in  
195 the AMLSG cohort. However, when aggregating mutations at the gene level, mutations in  
196 *SRSF2* and *SF3B1* presented with prognostic relevance for RFS in the AMLSG cohort  
197 (HR=1.77,  $p=0.008$ ; HR=2.15,  $p=0.014$ ; respectively), while not reaching significance in the  
198 AMLCG cohort (Table S4.2). When looking only at de novo AML patients, the prognostic  
199 impact of *U2AF1*(S34F) mutations diminished, yet the prognostic impact observed for *SRSF2*  
200 and *SF3B1* remained significant in the AMLSG cohort (HR=1.84,  $p=0.009$ ; HR=2.43,  $p=0.015$ ;  
201 respectively) (Tables S4.1-S4.2).

## 202 **Differential isoform expression in SF mutated patients**

203 We next assessed the impact of SF mutations on mRNA expression. To this end, whole-  
204 transcriptome RNA-sequencing was performed on 246 AML patients, 29 of which harbored a  
205 mutation in the SF genes of interest, while 199 SF wildtype patients were used as a control  
206 (Figure S2). The remaining patients either presented with a different SF mutation ( $n=17$ ) or  
207 exhibited more than one SF mutation ( $n=1$ ) and were excluded. In addition, a subset of the  
208 Beat AML cohort ( $n=177$ ) with matched DNA- and RNA-sequencing data was used for  
209 validation [20].

210 After low-coverage filtering we performed a differential isoform expression analysis for ~90  
211 000 isoforms. Differential expression was restricted to a small fraction of all expressed  
212 isoforms ( $<0.5\%$ ; Figure 4A and Table S6.1). Little overlap of differentially expressed (DE)

213 isoforms was found when different SF mutation groups were compared to the control,  
214 consistent with previous observations [32]. However, 10 isoforms were reported as DE in both  
215 *SRSF2*(P95H) and *SRSF2*(P95L) mutated samples, all with the same fold-change direction  
216 (Figure 4B). Out of those, the isoforms in *GTF2I*, *H1FO*, *INHBC*, *LAMC1* and one of the  
217 isoforms of *METTL22* (*ENST00000562151*) were also significant in the validation cohort for  
218 both *SRSF2*(P95H) and *SRSF2*(P95L). Additionally, the isoform of *H1FO* was also reported as  
219 DE for *U2AF1*(S34F) mutants in both cohorts. For *SRSF2*(P95H) mutants 107 of all DE  
220 isoforms also reached significance in the validation cohort (40.1%), while for the other SF  
221 mutation subgroups validation rates ranged from 15.1 to 27.3% increasing with larger mutant  
222 sample sizes. Notably, mutated and wildtype samples showed large differences in the  
223 expression levels of several isoforms (Figure 4C and Figure S5). The top two overexpressed  
224 isoforms in *SRSF2*(P95H) both corresponded to *INTS3*, which was recently reported as  
225 dysregulated in *SRSF2*(P95H) mutants co-expressing *IDH2* mutations [33]. Several DE  
226 isoforms identified in SF mutated patients correspond to cancer-related genes, many of which  
227 have a known role in AML. Specifically, genes with DE isoforms included, but were not limited  
228 to *BRD4* [34], *EWSR1* [35] and *YBX1* [36] in *SRSF2*(P95H) mutated samples, *CUX1* [37],  
229 *DEK* [15,38] and *EZH1* [39] in *U2AF1*(S34F) mutated samples, as well as *PTK2* [40] in  
230 *SF3B1*(K700E) mutated patients (Tables S7.1-S7.2).

231 Hierarchical clustering using DE isoforms was performed for all samples to assess the  
232 expression homogeneity of SF mutations. A tight clustering of samples harboring identical SF  
233 point mutations was observed, indicating an isoform expression profile highly characteristic  
234 for each individual SF mutation (Figures S6.1-S6.3). When using DE isoforms resulting from  
235 the comparison of all *SRSF2* mutated samples against SF wildtype samples, the samples did  
236 not cluster as well. This stands in agreement with the limited overlap of differentially

237 expressed isoforms found between the two *SRSF2* point mutations examined and suggests at  
238 least some heterogeneity among them. The same also held true for *U2AF1* mutated samples,  
239 however all *SF3B1* mutated samples still clustered together when compared as a single  
240 group to the control.

#### 241 **Differential splicing in SF mutants**

242 Previous studies have reported differential splicing as causal for isoform dysregulation in SF  
243 mutants [41,42]. To detect aberrant splicing in our dataset, we quantified the usage of all  
244 unique splice junctions by pooling information from all samples (Figure S7). After filtering out  
245 junctions with low expression, 235 730 junctions were assigned to genes. Only junctions  
246 within an annotated gene were considered, leading to the exclusion of 11 617 (4.9%)  
247 junctions. Junctions present in genes with low-expression or genes with a single junction were  
248 excluded, leaving 221 249 unique junctions (19.3% novel) across 15 526 genes (Table S6.1).  
249 Applying the same workflow to the Beat AML cohort yielded 194 158 junctions (8.3% novel).  
250 Notably, of the 172 518 junctions shared across both datasets, 10 029 (5.8%) were novel. The  
251 novel junctions passing our filtering criteria were supported by a high amount of reads and  
252 samples with a distribution comparable to that of annotated junctions (Figure 5A). Neither the  
253 number of novel junctions nor the number of reads supporting them correlated with the  
254 presence of SF mutations, suggesting that novel splicing events are not increased in SF  
255 mutants.

256 In consideration of the high proportion of novel junctions in both datasets, we employed a  
257 customized pipeline that can quantify the differential splice junction usage (DSJU) of each  
258 individual junction, by harnessing usage information from all junctions inside one gene. Of the  
259 several hundred junctions reported as differentially used in our primary cohort ( $p < 0.05$ ,  
260  $\log_2(\text{fold change}) > 1$ ), 20.2-45.9% constituted novel junctions (Tables S7.1-S7.3 and Tables

261 S9.1-S9.2) and were classified according to their relationship with known acceptor and donor  
262 sites as described previously (Figure 5B) [15]. Unsurprisingly, validation rates increased with  
263 larger mutant sample sizes, ranging from 9.3% (*SF3B1*(K700E); n = 3) to 74.0% (all *SRSF2*  
264 mutants; n = 26). Furthermore, validation rates were higher for novel junctions (mean 39.3%  
265 vs. 21.5% known junctions), likely due to the stricter initial filtering criteria applied. By  
266 performing nanopore sequencing of one *SRSF2*(P95H) mutant and one SF wildtype sample  
267 we were able to confirm the usage of several novel junctions and detect resulting novel  
268 isoforms as exemplified for *IDH3G* in Figure 6A-D. A tendency towards decreased junction  
269 usage was observed for all SF point mutations and was most evident in *SF3B1*(K700E)  
270 mutants (1 423/1 927; 73.9% of differentially used junctions). The total number of splicing  
271 events, however, was not reduced in SF mutants (mean 9,275,359 events vs. 9 192 697 in  
272 wildtype patients), suggesting that decreased splicing is limited to selected junctions rather  
273 than being a global effect.

274 We systematically compared the genes with at least one DE isoform and those reported as  
275 differentially spliced in all SF mutation subgroups (Tables S9.3-S9.4). For *SRSF2* mutants,  
276 genes significant in both analyses included *EWSR1*, *H1FO*, *INTS3* and *YBX1*. In general, out  
277 of the genes examined in both analyses only 9.8-23.3% (depending on the SF mutation) of  
278 genes reported as having a DE isoform were also reported as being differentially spliced.  
279 Conversely, 3.3-28.5% of differentially spliced genes were also reported as having a DE  
280 isoform. These findings suggest that differential gene splicing does not always lead to altered  
281 isoform expression while at the same time differential isoform expression cannot always be  
282 attributed to an explicit splicing alteration. Considering the complementary nature of the  
283 analyses, we performed gene ontology (GO) analysis by combining the genes with evidence  
284 of differential isoform usage or differential splicing (Tables S10.1-S10.7). Interestingly, GO

285 terms enriched for both *SRSF2* mutants included “mRNA splicing, via spliceosome” ( $p < 0.001$   
286 and  $p = 0.046$ , respectively) and “mRNA splice site selection” ( $p = 0.022$  and  $p = 0.019$ ,  
287 respectively) (Figure 5C).

288 In an additional step, the splice junction counts reported by *Okeyo-Owuor et al.* were used to  
289 detect DSJU between CD34+ cells with *U2AF1*(S34) mutations ( $n = 3$ ) and SF wildtype ( $n = 3$ )  
290 via the same pipeline applied to the AMLCG and Beat AML cohorts. While no identical  
291 junctions were differentially used in all three datasets, 16 genes were reported as differentially  
292 spliced in all, including leukemia or cancer-associated genes (*ABI1*, *DEK*, *HP1BP3*, *MCM3*  
293 and *SET*), as well as *HNRNPK* (a major pre-mRNA binding protein), thereby further refining  
294 our list of genes with strong evidence of differential splicing between *U2AF1*(S34F) mutants  
295 and SF wildtype samples (Table S11).

#### 296 **The effect of SF mutations on the splicing pathway**

297 It is well established that SF mutations dysregulate splicing by changing RNA binding affinities  
298 or altering 3' splice site recognition of the corresponding splicing factors. However, *SRSF2*  
299 also plays a splicing-independent role in transcriptional pausing by translocating the positive  
300 transcription elongation factor complex (P-TEFb) from the 7SK complex to RNA polymerase II  
301 [43]. A recent study reported that mutant *SRSF2*(P95H) enhances R-loop formation due to  
302 impaired transcriptional pause release, thus providing evidence that altered splicing does not  
303 account for the entirety of the *SRSF2*(P95H) mutant phenotype [32]. In another study no  
304 difference was found in the total mRNA of 12 Serine/arginine rich splicing factors and 14 out  
305 of 16 major heterogeneous nuclear ribonucleoprotein (hnRNP) splicing factors between  
306 *SRSF2*(P95H) mutant and WT CRISPR clones [44].

307 We cross-referenced our differential expression and differential splicing analysis results with a  
308 list of all genes involved in splicing (GO:0000398; mRNA splicing, via spliceosome). Of the



309 347 splicing-related genes (317 of which were expressed in our dataset) 101 were  
310 dysregulated in at least one SF mutant group. On average 30.5 (range 6-52) splicing-related  
311 genes were dysregulated per SF point mutation. Of note, both *SRSF2* point mutations  
312 associated with differential splicing of *HNRNPA1* and *HNRNPUL1*, as well as *PCF11* and  
313 *TRA2A*. A query of the STRING database suggests protein-protein interactions between  
314 *SRSF2* and the proteins of the above genes, which are also interconnected (Figure 6E).  
315 Interestingly, one of the differential splicing events reported in both *SRSF2* mutants involves  
316 the under-usage of the same novel splice junction in *TRA2A* (Figure 6F). *TRA2A* has  
317 previously been shown to be differentially spliced in mouse embryo fibroblasts upon *SRSF2*  
318 knockout [45]. Furthermore, it has been shown that both *HNRNPA1* and *SRSF2* interact with  
319 the loop 3 region of 7SK RNA and by favoring the dissociation of *SRSF2*, *HNRNPA1* may  
320 lead to the release of active P-TEFb [46]. Taken together, our results indicate a strong  
321 dysregulation of the splicing pathway in SF mutants including several genes whose gene  
322 products closely interact with *SRSF2*.

323

324



## 325 **Discussion**

326 The clinical relevance of SF mutations and their aberrant splicing patterns have been  
327 explored in myelodysplasia, while comparable data for AML is lacking. In this study we  
328 examined two AML patient cohorts, encompassing a total of 2678 patients from randomized  
329 prospective trials, to characterize SF mutations clinically. This analysis was complemented by  
330 RNA-sequencing analysis of two large datasets to reveal targets of aberrant splicing in AML.

331 We show that SF mutations are frequent alterations in AML, identified in 21.4% of our primary  
332 patient cohort, especially in elderly patients and in secondary AML. SF mutations are  
333 associated with other recurrent mutations in AML, such as *BCOR* and *RUNX1* mutations,  
334 however *SRSF2*(P95L) mutations co-occur less often with those mutations when compared to  
335 *SRSF2*(P95H) mutations, albeit showing a slightly increased mutational load. This suggests a  
336 more diverse co-expression profile of *SRSF2*(P95L).

337 Previous studies have demonstrated the predictive value of SF mutations in clonal  
338 haematopoiesis of indeterminate potential (CHIP) [47], MDS [6,8,48–50] and AML  
339 [10,18,19,51]. However, survival analyses in AML were, in their majority, hampered by small  
340 sample sizes and limited availability of further risk factors. Therefore, we examined whether  
341 SF mutations impact survival while accounting for recently proposed risk parameters included  
342 in the ELN 2017 classification [52]. In our analysis, *SRSF2* and *SF3B1* mutations were no  
343 independent prognostic markers for OS in AML. *U2AF1*(S34F) mutations displayed poor OS  
344 in the AMLCG cohort, which we were unable to validate in the AMLSG cohort. The  
345 discrepancy in survival of SF mutated patients between the two cohorts lied most likely in the  
346 large age difference of the participants (median age difference of 8 years), which also led to a  
347 higher percentage of patients receiving allogeneic transplants in the AMLSG cohort (56.5%  
348 vs. 30.6% in the AMLCG cohort). In summary, SF mutations are early evolutionary events and

349 define prognosis and transformation risk in CHIP and MDS patients, yet there is no clear  
350 independent prognostic value of SF mutations in AML.

351 Two large RNA-sequencing studies have been performed previously, to detect aberrantly  
352 spliced genes in SF mutants, both of which focused on MDS patients [41,42]. In this study we  
353 described a distinct differential isoform expression profile for each SF point mutation.

354 Furthermore, we evaluated differential splicing for the four most common SF point mutations  
355 via a customized pipeline to determine differential usage of both known and novel splice  
356 junctions. Our pipeline enables the differential quantification of individual splice junctions  
357 without restricting the analysis to annotated alternative splicing events. We argue that the  
358 strength of our analysis lies in the accurate detection of single dysregulated junctions  
359 (especially in cases where splice sites are shared by multiple junctions) in an annotation-  
360 independent manner achieving validation rates up to 74.0% in our largest mutant sample  
361 group (*SRSF2*, n=19). Limitations of the analysis include the restriction to junctions with both  
362 splice sites within the same gene (a restriction shared by most differential splicing algorithms)  
363 and genes with at least two junctions. However, the reduced requirements of our analysis  
364 could prove valuable in the study of differential splicing in organisms with lacking annotation.

365 All SF point mutations shared a tendency towards decreased splice junction usage, which did  
366 not affect the global number of splicing events in SF mutants. Surprisingly, we observed a  
367 limited overlap between genes with differentially expressed isoforms and differentially spliced  
368 genes. In addition, a recent study by *Liang et al.* reported that the majority of differential  
369 binding events in *SRSF2*(P95H) mutants do not translate to alternative splicing [53]. Taken  
370 together, these findings indicate a “selection” or possibly a compensation of deregulatory  
371 events from differential binding through differential splicing to finally differential isoform  
372 expression. Furthermore, the enrichment of aberrant splicing in splicing-related genes opens

373 the possibility of a cascading effect on transcription via the differential alternative splicing of  
374 transcriptional components. A congruent hypothesis was stated by *Liang et al.*, where an  
375 enrichment of *SRSF2*(P95H) targets in RNA processing and splicing was shown, further  
376 supporting the notion of an indirect effect of mutant *SRSF2* facilitated through additional  
377 splicing components. Further investigations may provide a mechanistic link between the  
378 differential splicing of selected genes and the impairment of transcription and specifically  
379 transcriptional pausing observed in SF mutant cells, which contributes to the MDS phenotype  
380 [32].

381 To the best of our knowledge our study represents the most comprehensive analysis of SF  
382 mutations in AML to date, both in terms of clinical and functional characterization. This  
383 enabled us to study *SRSF2*(P95H) and *SRSF2*(P95L) separately, thereby not only outlining  
384 their differences but also identifying common and likely core targets of differential splicing in  
385 *SRSF2* mutants. We conclude that SF mutated patients represent a distinct subgroup of AML  
386 patients with poor prognosis that is not attributable solely to the presence of SF mutations. SF  
387 mutations induce aberrant splicing throughout the genome including the dysregulation of  
388 several genes associated with AML pathogenesis, as well as a number of genes with  
389 immediate, functional implications on splicing and transcription. Further studies are required  
390 to identify which splicing events are critical in leukaemogenesis and whether they are  
391 accessible to new treatments options, such as splicing inhibitors [54] and immunotherapeutic  
392 approaches.

393 **Acknowledgments**

394 The authors thank all participants and recruiting centers of the AMLCG, BEAT and AMLSG  
395 trials.

396

397 **Funding**

398 This work is supported by a grant of the Wilhelm-Sander-Stiftung (no. 2013.086.2) and the  
399 Physician Scientists Grant (G-509200-004) from the Helmholtz Zentrum München to T.H. and  
400 the German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung,  
401 Heidelberg, Germany). K.H.M., K.S. and T.H. are supported by a grant from Deutsche  
402 Forschungsgemeinschaft (DFG SFB 1243, TP A06 and TP A07). S.K.B. is supported by  
403 Leukaemia & Blood Cancer New Zealand and the family of Marijanna Kumerich. A.M.N.B. is  
404 supported by the BMBF grant 01ZZ1804B (DIFUTURE).

405

406 **Author Contributions**

407 S.A.B., A.M.N.B. and T.H. conceived and designed the analysis. S.A.B., A.M.N.B., V.J., M.R.-  
408 T., H.J., A.G., S.C., N.K., K.S., K.H.M. and T.H. provided and analyzed data. A.M.N.B., V.J.  
409 and U.M. provided bioinformatics support. J.P.-M., S.K. and H.B. managed the Genome  
410 Analyzer Ix platform and the RNA-sequencing of the AMLCG samples. M.R.-T., H.J., B.K.,  
411 S.S., N.K., S.K.B., K.H.M. and K.S. characterized patient samples; M.C.S., D.G., W.B., B.W.,  
412 J.B. and W.H. coordinated the AMLCG clinical trials. S.A.B. and T.H. wrote the manuscript. All  
413 authors approved the final manuscript.

414

415 **Additional Information**

416 The authors declare no conflicts of interest.

417 **References**

- 418 1. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al.  
419 Clinical and biological implications of driver mutations in myelodysplastic syndromes.  
420 2013;122(22):3616–27.
- 421 2. Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D, et al.  
422 Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.  
423 2016;128(5):686–98.
- 424 3. Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Kar SA, Jerez A, et al.  
425 Mutations in the spliceosome machinery, a novel and ubiquitous pathway in  
426 leukemogenesis. 2012;119(14):3203–10.
- 427 4. Larsson CA, Cote G, Quintás-Cardama A. The changing mutational landscape of acute  
428 myeloid leukemia and myelodysplastic syndrome. 2013;11(8):815–27.
- 429 5. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent  
430 pathway mutations of splicing machinery in myelodysplasia. 2011;478(7367):64–9.
- 431 6. Thol F, Kade S, Schlarman C, Löffeld P, Morgan M, Krauter J, et al. Frequency and  
432 prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with  
433 myelodysplastic syndromes. 2012;119(15):3578–84.
- 434 7. Dolatshad H, Pellagatti A, Fernandez-Mercado M, Yip BH, Malcovati L, Attwood M, et  
435 al. Disruption of SF3B1 results in deregulated expression and splicing of key genes and  
436 pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.  
437 2015;29(5):1092–103.
- 438 8. Wu S, Kuo Y, Hou H, Li L, Tseng M, Huang C, et al. The clinical implication of SRSF2  
439 mutation in patients with myelodysplastic syndrome and its stability during disease

- 440 evolution. 2014;120(15):3106–12.
- 441 9. Graubert TA, Shen D, Ding L, Okeyo-owuor T, Cara L, Shao J, et al. Recurrent  
442 Mutations in the U2AF1 Splicing Factor In Myelodysplastic Syndromes. 2012;44(1):53–  
443 7.
- 444 10. Hou H-A, Liu C-Y, Kuo Y-Y, Chou W-C, Tsai C-H, Lin C-C, et al. Splicing factor  
445 mutations predict poor prognosis in patients with de novo acute myeloid leukemia.  
446 2016;7(8).
- 447 11. Cho Y-U, Jang S, Seo E-J, Park C-J, Chi H-S, Kim D-Y, et al. Preferential occurrence of  
448 spliceosome mutations in acute myeloid leukemia with a preceding myelodysplastic  
449 syndrome and/or myelodysplasia morphology. 2014;8194(November):1–25.
- 450 12. Moon H, Cho S, Loh TJ, Jang HN, Liu Y, Choi N, et al. SRSF2 directly inhibits intron  
451 splicing to suppresses cassette exon inclusion. 2017;50(8):423–8.
- 452 13. Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SCW, Ramakrishnan A, et al. SRSF2  
453 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon  
454 Recognition. 2015;27(5):617–30.
- 455 14. Alsafadi S, Houy A, Battistella A, Popova T, Wassef M, Henry E, et al. Cancer-  
456 associated SF3B1 mutations affect alternative splicing by promoting alternative  
457 branchpoint usage. 2016;7:10615.
- 458 15. Okeyo-Owuor T, White BS, Chatrikhi R, Mohan DR, Kim S, Griffith M, et al. U2AF1  
459 mutations alter sequence specificity of pre-mRNA binding and splicing. 2015;29(4):909–  
460 17.
- 461 16. Przychodzen B, Jerez A, Guinta K, Sekeres MA, Padgett R, Maciejewski JP, et al.

- 462           Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms.  
463           2013;122(6):999–1006.
- 464   17.   Shirai CL, Ley JN, White BS, Kim S, Tibbitts J, Shao J, et al. Mutant U2AF1 Expression  
465           Alters Hematopoiesis and Pre-mRNA Splicing In Vivo. 2015;27(5):631–43.
- 466   18.   Yang J, Yao D, Ma J, Yang L, Guo H, Wen X, et al. The prognostic implication of SRSF2  
467           mutations in Chinese patients with acute myeloid leukemia. 2016;37(8):10107–14.
- 468   19.   Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al.  
469           Genomic Classification and Prognosis in Acute Myeloid Leukemia. 2016;374(23):2209–  
470           21.
- 471   20.   Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional  
472           genomic landscape of acute myeloid leukaemia. 2018;562(7728):526–31.
- 473   21.   Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast  
474           universal RNA-seq aligner. 2013;29(1):15–21.
- 475   22.   Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-  
476           aware quantification of transcript expression. 2017;14(4):417–9.
- 477   23.   Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential  
478           expression analyses for RNA-sequencing and microarray studies. 2015;43(7):e47–e47.
- 479   24.   Robinson MD, Oshlack A. A scaling normalization method for differential expression  
480           analysis of RNA-seq data. 2010;11(3):R25.
- 481   25.   Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor package for differential  
482           expression analysis of digital gene expression data. 2009;26(1):139–40.
- 483   26.   Liu R, Holik AZ, Su S, Jansz N, Chen K, Leong HS an, et al. Why weight? Modelling

- 484 sample and observational level variability improves power in RNA-seq analyses.  
485 2015;43(15):e97.
- 486 27. Law CW, Chen Y, Shi W, Smyth GK. voom: precision weights unlock linear model  
487 analysis tools for RNA-seq read counts. 2014;15(2):R29.
- 488 28. Leek JT. Svaseq: Removing batch effects and other unwanted noise from sequencing  
489 data. 2014;42(21):e161.
- 490 29. Tang AD, Soulette CM, Baren MJ van, Hart K, Hrabeta-Robinson E, Wu CJ, et al. Full-  
491 length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia  
492 reveals downregulation of retained introns. 2018;410183.
- 493 30. R Core Team. R: A Language and Environment for Statistical Computing [Internet].  
494 Vienna, Austria: R Foundation for Statistical Computing;
- 495 31. Herold T, Metzeler KH, Vosberg S, Hartmann L, Ollig C, Olzel FS, et al. Isolated trisomy  
496 13 defines a homogeneous AML subgroup with high frequency of mutations in  
497 spliceosome genes and poor prognosis. 2014;124(8):1304–11.
- 498 32. Chen L, Chen J-Y, Huang Y-J, Gu Y, Qiu J, Qian H, et al. The Augmented R-Loop Is a  
499 Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing  
500 Factor Mutations. 2018;69(3):412-425.e6.
- 501 33. Yoshimi A, Lin K-T, Wiseman DH, Rahman MA, Pastore A, Wang B, et al. Coordinated  
502 alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.  
503 2019;574(7777):273–7.
- 504 34. Roe J-S, Vakoc CR. The Essential Transcriptional Function of BRD4 in Acute Myeloid  
505 Leukemia. 2016;81:61–6.



- 506 35. Endo A, Tomizawa D, Aoki Y, Morio T, Mizutani S, Takagi M. EWSR1/ELF5 induces  
507 acute myeloid leukemia by inhibiting p53/p21 pathway. 2016;107(12):1745–54.
- 508 36. Perner F, Jayavelu AK, Schnoeder TM, Mashamba N, Mohr J, Hartmann M, et al. The  
509 Cold-Shock Protein Ybx1 Is Required for Development and Maintenance of Acute  
510 Myeloid Leukemia (AML) in Vitro and In Vivo. 2017;130(Suppl 1).
- 511 37. McNerney ME, Brown CD, Wang X, Bartom ET, Karmakar S, Bandlamudi C, et al.  
512 CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently  
513 inactivated in acute myeloid leukemia. 2013;121(6):975–83.
- 514 38. McGarvey T, Rosonina E, McCracken S, Li Q, Arnaout R, Mientjes E, et al. The acute  
515 myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with  
516 exon-product complexes. 2000;150(2):309–20.
- 517 39. Fujita S, Honma D, Adachi N, Araki K, Takamatsu E, Katsumoto T, et al. Dual inhibition  
518 of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.  
519 2018;32(4):855–64.
- 520 40. Pallarès V, Hoyos M, Chillón MC, Barragán E, Prieto Conde MI, Llop M, et al. Focal  
521 Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute  
522 Myeloid Leukemia. 2018;10(11).
- 523 41. Shiozawa Y, Malcovati L, Galli A, Sato-Otsubo A, Kataoka K, Sato Y, et al. Aberrant  
524 splicing and defective mRNA production induced by somatic spliceosome mutations in  
525 myelodysplasia. 2018;9(1):3649.
- 526 42. Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, et al. Impact of  
527 spliceosome mutations on RNA splicing in myelodysplasia: Dysregulated  
528 genes/pathways and clinical associations. 2018;132(12):1225–40.

- 529 43. Ji X, Zhou Y, Pandit S, Huang J, Li H, Lin CY, et al. SR Proteins Collaborate with 7SK  
530 and Promoter-Associated Nascent RNA to Release Paused Polymerase.  
531 2013;153(4):855–68.
- 532 44. Zhang J, Lieu YK, Ali AM, Penson A, Reggio KS, Rabadan R, et al. Disease-associated  
533 mutation in SRSF2 misregulates splicing by altering RNA-binding affinities.  
534 2015;112(34):E4726–34.
- 535 45. Skrdlant L, Stark JM, Lin R-J. Myelodysplasia-associated mutations in serine/arginine-  
536 rich splicing factor SRSF2 lead to alternative splicing of CDC25C. 2016;17(1):18.
- 537 46. Lemieux B, Blanchette M, Monette A, Mouland AJ, Wellinger RJ, Chabot B. A Function  
538 for the hnRNP A1/A2 Proteins in Transcription Elongation. Caputi M, editor.  
539 2015;10(5):e0126654.
- 540 47. Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, et al.  
541 Prediction of acute myeloid leukaemia risk in healthy individuals. 2018;559(7714):400–  
542 4.
- 543 48. Malcovati L, Papaemmanuil E, Bowen DT, Boulwood J, Della Porta MG, Pascutto C, et  
544 al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and  
545 myelodysplastic/myeloproliferative neoplasms. 2011;118(24):6239–46.
- 546 49. Papaemmanuil E, Cazzola M, Boulwood J, Malcovati L, Vyas P, Bowen D, et al.  
547 Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. 2011;365(15):1384–  
548 95.
- 549 50. Wu L, Song L, Xu L, Chang C, Xu F, Wu D, et al. Genetic landscape of recurrent  
550 ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with  
551 myelodysplastic syndromes. 2016;37(4):4633–40.

- 552 51. Zhang S-J, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, et al. Genetic  
553 analysis of patients with leukemic transformation of myeloproliferative neoplasms  
554 shows recurrent SRSF2 mutations that are associated with adverse outcome.  
555 2012;119(19):4480–5.
- 556 52. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al.  
557 Diagnosis and management of AML in adults: 2017 ELN recommendations from an  
558 international expert panel [Internet]. Vol. 129, Blood. 2017 [cited 2019 Feb 14]. p. 424–  
559 47.
- 560 53. Liang Y, Tebaldi T, Rejeski K, Joshi P, Stefani G, Taylor A, et al. SRSF2 mutations drive  
561 oncogenesis by activating a global program of aberrant alternative splicing in  
562 hematopoietic cells. 2018;
- 563 54. Lee SCW, Abdel-Wahab O. Therapeutic targeting of splicing in cancer [Internet]. Vol.  
564 22, Nature Medicine. NIH Public Access; 2016 [cited 2019 Jan 31]. p. 976–86.
- 565
- 566

567

**Table 1: Clinical characteristics of SF mutations in the AMLCG cohort.**

Variables	SF wildtype	SRSF2	P	U2AF1	P	SF3B1	P
No. of patients	903	133	-	38	-	45	-
Age, years, median (range)	55 (18-86)	65 (25-80)	<b>&lt;0.001</b>	64 (23-74)	<b>0.007</b>	65 (31-78)	<b>0.001</b>
Female sex, no. (%)	490 (54.3)	31 (23.3)	<b>&lt;0.001</b>	9 (23.7)	<b>0.003</b>	19 (42.2)	0.387
Hemoglobin, g/dL, median (range)	9 (3.5-16)	8.9 (3.8-14.7)	0.466	9.2 (6-13.6)	1.000	8.9 (6.8-13.4)	1.000
WBC count, 10 <sup>9</sup> /L, median (range)	22.4 (0.1-798.2)	13.3 (0.5-406)	<b>0.008</b>	7 (0.7-666)	0.079	22.4 (0.9-269.5)	1.000
Platelets, 10 <sup>9</sup> /L, median (range)	55 (0-1760)	49.5 (0-643)	0.736	47 (11-132)	0.466	67 (5-585)	0.744
LDH, U/L, median (range)	448 (76-19624)	362 (150-14332)	0.118	346 (128-3085)	0.313	472 (142-7434)	0.950
BM Blasts, %, median (range)	80 (6-100)	76 (15-100)	0.455	60 (10-95)	<b>0.002</b>	70 (13-95)	0.206
Performance Status (ECOG) > 1, no. (%)	157 (25.9)	18 (26.1)	1.000	8 (27.6)	1.000	4 (16)	0.941
primary AML, no. (%)	786 (87)	100 (75.2)	<b>0.016</b>	24 (63.2)	<b>0.003</b>	29 (64.4)	<b>0.002</b>
secondary AML, no (%)	69 (7.6)	30 (22.6)	<b>&lt;0.001</b>	13 (34.2)	<b>&lt;0.001</b>	11 (24.4)	<b>0.021</b>
therapy-related AML, no (%)	48 (5.3)	3 (2.3)	0.507	1 (2.6)	1.000	5 (11.1)	0.380
Allogeneic transplant, no. (%)	296 (32.8)	27 (20.3)	<b>0.022</b>	7 (18.4)	0.273	12 (26.7)	0.797
Complete Remission, no. (%)	641 (71)	71 (53.4)	<b>&lt;0.001</b>	18 (47.4)	<b>0.015</b>	19 (42.2)	<b>0.001</b>
Relapse, no (%)	366 (63.5)	46 (82.1)	<b>0.034</b>	11 (78.6)	0.713	14 (87.5)	0.266
Deceased, no (%)	575 (63.7)	112 (84.2)	<b>&lt;0.001</b>	34 (89.5)	<b>0.010</b>	41 (91.1)	<b>0.002</b>

568

569 WBC: white blood cells, LDH: lactate dehydrogenase, BM: bone marrow, ECOG: Eastern Co-  
 570 operative Oncology Group performance score

571

572

573

574

## 575 **Figure Legends**

576 **Figure 1: Frequency and location of SF mutations.** (A) Distribution of SF mutations in the  
577 AMLCG cohort. (B) Variant allele frequency of SF mutations in both study cohorts. (C)  
578 Mutation plots showing the protein location of all SF mutations in the genes *SRSF2*, *U2AF1*,  
579 and *SF3B1* for all patients of the AMLCG cohort. Number of patients harboring SF mutations  
580 are additionally provided for both cohorts.

581 **Figure 2: Correlations between SF mutations and recurrent abnormalities.** Correlation  
582 matrix depicting the co-occurrence of SF mutations and recurrent mutations in AML (A), as  
583 well as cytogenetic groups, as defined in the ELN 2017 classification (B). Only variables with  
584 a frequency >1% in the AMLCG cohort are shown. FLT3-ITD: *FLT3* internal tandem  
585 duplication mutation; FLT3-TKD: *FLT3* tyrosine kinase domain mutation; CN-AML:  
586 cytogenetically normal AML

587 **Figure 3: Multiple Cox regression models for overall survival.** Multiple Cox regression  
588 models (for OS) were performed separately for patients in the AMLCG cohort (on the left) and  
589 AMLSG cohort (on the right). The models include all variables with  $p < 0.1$  in the single Cox  
590 regression models of the primary cohort (AMLCG cohort). Significant p-values (<0.05) are  
591 marked with a star. CN-AML: cytogenetically normal AML; LDH: lactate dehydrogenase;  
592 pAML: primary AML; sAML: secondary AML; tAML: therapy-related AML; WBC: white blood  
593 cells

594 **Figure 4: Differential isoform expression analysis in the AMLCG cohort.** (A) Number of  
595 differentially expressed isoforms for each SF point mutation. (B) Isoforms reported as  
596 differentially expressed in the same direction among patients with different SF mutations vs.  
597 SF wildtype patients. HGNC symbols of the genes in which the common isoforms are located  
598 are shown. The corresponding Ensembl isoform identifiers are: 1. ENST00000340857, 2.

599 ENST00000481621, 3. ENST00000309668, 4. ENST00000258341, 5. ENST00000426532, 6.  
600 ENST00000562151, 7. ENST00000564133, 8. ENST00000368817, 9. ENST00000566524,  
601 10. ENST00000530211. (C) Volcano plots showing the magnitude of differential isoform  
602 expression for *SRSF2*(P95H) and *SRSF2*(P95L). The x-axis corresponds to the  $\log_2$ (fold  
603 change) of each isoform between mutated and wildtype samples, while the y-axis  
604 corresponds to  $-\log_{10}$ (FDR), where FDR represents the adjusted p-value for each isoform  
605 (False Discovery Rate).

606 **Figure 5: Differential splice junction usage.** (A) Scatterplot displaying the number of  
607 samples as well as the total number of reads supporting each splice junction, separately for  
608 known and novel splice junctions in both RNA-Seq datasets. To preserve visibility 20000  
609 random junctions are shown for each group. (B) Barchart showing the annotation status of  
610 splice junctions reported as differentially used. Novel splice junctions were classified into 5  
611 groups based on their annotation status as described previously[15] (“DA”: annotated  
612 junctions, “NDA”: unknown combination of known donor and acceptor sites, “D”: known donor,  
613 but novel acceptor site, “A”: novel donor, but known acceptor site, “N”: previously unknown  
614 donor and acceptor site). (C) Venn diagram showing the overlap of GO terms between  
615 *SRSF2*(P95H) and *SRSF2*(P95L) mutants for the “biological process” domain.


616 **Figure 6: Splicing dysregulation in *SRSF2* mutants.** (A) DSJU of all splice junctions inside  
617 *IDH3G* (ENSG00000067829) are shown for *SRSF2*(P95H) mutants compared to SF wildtype  
618 patients in the AMLCG and Beat AML cohort. To determine significance the log fold-change  
619 (logFC) of each splice junction (SJ) is compared to the logFC of all other junctions inside the  
620 same gene. The x-axis denotes individual splice junctions defined by their chromosomal  
621 coordinates (note the high number of splice sites shared by multiple splice junctions). (B)-(D)  
622 Nanopore sequencing results of one *SRSF2*(P95H) mutated sample and one SF wildtype

623 sample of the AMLCG cohort. The yellow boxes highlight examples of exon skipping (same  
624 exons highlighted in (C) and (D). (B) FLAIR distribution of transcripts. Only one known isoform  
625 is expressed in the samples. Additionally, two novel isoforms were detected which are virtually  
626 mutually exclusive in the *SRSF2*(P95H) mutant and the SF wildtype sample. (C) Exon  
627 composition of known and novel isoforms detected (D). Sashimi plots showing the exon  
628 sequence coverage as well as the splice junction usage of the *SRSF2*(P95H) mutated and SF  
629 wildtype samples. The black arrow indicates the novel splice junction that is differentially used  
630 in *SRSF2*(P95H) mutated samples compared to SF wildtype samples in both RNA-Seq  
631 datasets shown in (A). (E) STRING plot depicting an interaction between *SRSF2* and several  
632 other splicing-related proteins including *TRA2A*. (F) Differential splice junction usage of all  
633 splice junctions inside *TRA2A* (ENSG00000164548) are shown for *SRSF2*(P95H) and  
634 *SRSF2*(P95L) mutants compared to SF wildtype patients. Annotation same as (A).

635

636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673


**Figure 1**






674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721

Figure 2




722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769

Figure 3




770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812

Figure 4



813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860

Figure 5



861  
862  
863

Figure 6

